Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET

Company Participants

Al Sandrock - Chief Executive Officer

Todd Carter - Chief Scientific Officer

Pete Pfreundschuh - Chief Financial Officer

Allen Nunnally - Chief Business Officer

Conference Call Participants

Jack Allen - Baird

Joon Lee - Truist

Dane Leone - Raymond James

Yun Zhong - BTIG

Laura Chico - Wedbush

Yanan Zhu - Wells Fargo

Jay Olson - Oppenheimer

Operator

Good morning and welcome to Voyager Therapeutics 2022 Fourth Quarter and Year End Conference Call. All participants are now in listen-only mode. [Operator Instructions] Please be advised this call is being recorded at the company’s request. A replay of today’s call will be available on the Investor section of the company’s website approximately 2 hours after completion of this call.

I would now like to turn the call over to Pete Pfreundschuh, Chief Financial Officer.

Pete Pfreundschuh

Thank you and good morning. Joining me on today’s call are Dr. Al Sandrock, our CEO; Dr. Todd Carter, our Chief Scientific Officer; and Allen Nunnally, our Chief Business Officer. We issued our Q4 and year end 2022 press release this morning. The press release and 10-K are available on our website. We plan to provide a brief summary of key highlights from the quarter and reserve the majority of time for your Q&A.

In a moment, I will turn the call over to Al. Before I do this, I want to remind everyone that during this call, Voyager representatives may make forward-looking statements regarding future expectations, plans and prospects. All forward-looking statements are inherently uncertain and are subject to risks and uncertainties that may cause actual results to differ materially from those indicated by these forward-looking statements. You are encouraged to review and understand a number of the material risks and uncertainties facing the company as described in the company’s annual report on Form 10-K filed with the SEC this morning. All SEC filings are available on the company’s website.

Now, it is my pleasure to turn the call over to Al.

Al Sandrock

Thank you, Pete and good morning everyone. I would like to start by acknowledging the transformation Voyager has undergone in 2022. Since I became CEO last March, we have advanced a pipeline focused on some of the most significant unmet needs in neurology, achieved breakthrough innovations in novel capsid discovery, including the identification of a receptor for one class of capsids and entered multiple high value collaborations. Thanks to this progress during a time when markets have been very difficult for much of the sector, we have created value for shareholders and we have made important steps towards creating value for patients. I believe we will continue to do so as we focus on the three pillars of our investment rationale.